AR128280A1 - Derivados de bencimidazol piridina - Google Patents
Derivados de bencimidazol piridinaInfo
- Publication number
- AR128280A1 AR128280A1 ARP230100104A ARP230100104A AR128280A1 AR 128280 A1 AR128280 A1 AR 128280A1 AR P230100104 A ARP230100104 A AR P230100104A AR P230100104 A ARP230100104 A AR P230100104A AR 128280 A1 AR128280 A1 AR 128280A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycloalkyl
- cycloalkyl
- compound
- cycloalkylalkyl
- Prior art date
Links
- BUTGVBZBUDLKCM-UHFFFAOYSA-N 1h-benzimidazole;pyridine Chemical class C1=CC=NC=C1.C1=CC=C2NC=NC2=C1 BUTGVBZBUDLKCM-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 10
- 150000001875 compounds Chemical class 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 7
- 125000001188 haloalkyl group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 4
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 3
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 3
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- -1 hydroxycarbonylamino Chemical group 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 2
- 150000001412 amines Chemical class 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 239000003054 catalyst Substances 0.000 abstract 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 229910052763 palladium Inorganic materials 0.000 abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 208000003456 Juvenile Arthritis Diseases 0.000 abstract 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
- 150000001543 aryl boronic acids Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 208000019069 chronic childhood arthritis Diseases 0.000 abstract 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 abstract 1
- 125000004992 haloalkylamino group Chemical group 0.000 abstract 1
- 125000005347 halocycloalkyl group Chemical group 0.000 abstract 1
- 125000005059 halophenyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000010157 sclerosing cholangitis Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) en donde R¹ es hidrógeno o alcoxi; R² es hidrógeno, alquilo, amino, alquilamino, dialquilamino, haloalquilo, haloalquilamino, cicloalquilamino, hidroxi, alcoxi, cicloalquilo, cicloalquiloxi o haloalcoxi; A¹ es -O-, -NR⁶- o un enlace; R⁶ es hidrógeno o alquilo; R³ es alquilo, haloalquilo, hidroxialquilo, heterocicloalquilo, heteroarilo, fenilo, heteroarilalquilo, fenilalquilo, cicloalquilo, cicloalquilalquilo, (amino)(fenil)alquilo, (amino)(halofenil)alquilo o (amino)(heteroaril)alquilo, en donde heterocicloalquilo, heteroarilo, fenilo, heteroarilalquilo, fenilalquilo, cicloalquilo y cicloalquilalquilo están opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados independientemente de R⁷; cada R⁷ se selecciona independientemente de alcoxi, alquilamino, alquilo, aminocarbonilo, amino, ciano, cicloalquilamino, haloalquilo, halocicloalquilo, halógeno, heteroarilo, hidroxicarbonilamino, alcoxialquilo, alquilaminocarbonilo, alquilsulfonilo, aminocarbonilo, hidroxi, cicloalquilalquilo, haloalcoxi, heterocicloalquilo y cicloalquilo; R⁴ es hidrógeno, alquilo, halógeno, ciano, haloalquilo, alcoxi, alcoxialquilo, dialquilaminoalquilo, dialquilamino, alquilamino, alquilaminoalquilo, cicloalquilo, cicloalquilamino, cicloalquiloxi, cicloalquilalquilo, heteroarilalquilo, heteroarilamino, heteroariloxi, heterocicloalquilo, heterocicloalquilamino, heterocicloalquiloxi o heterocicloalquilalquilo; en donde cicloalquilo, cicloalquilamino, cicloalquiloxi, cicloalquilalquilo, heteroarilalquilo, heteroarilamino, heteroariloxi, heterocicloalquilo, heterocicloalquilamino, heterocicloalquiloxi y heterocicloalquilalquilo están opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados independientemente de R⁸; cada R⁸ se selecciona independientemente de alquilo, halógeno, ciano,alquilsulfonilo, alquilaminocarbonilo, heterocicloalquilo y alcoxiheterocicloalquilalquilo; R⁵ es hidrógeno, alquilo, halógeno, ciano, haloalquilo, alcoxi, alcoxialquilo, dialquilaminoalquilo, dialquilamino, alquilamino, alquilaminoalquilo, alquilsulfonilo, cicloalquilo, cicloalquilamino, cicloalquiloxi, cicloalquilalquilo, heteroarilalquilo, heteroarilamino, heteroariloxi, heterocicloalquilo, heterocicloalquilamino, heterocicloalquiloxi o heterocicloalquilalquilo; en donde cicloalquilo, cicloalquilamino, cicloalquiloxi, cicloalquilalquilo, heteroarilalquilo, heteroarilamino, heteroariloxi, heterocicloalquilo, heterocicloalquilamino, heterocicloalquiloxi y heterocicloalquilalquilo están opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados independientemente de R⁹; o R⁴ y R⁵, junto con el carbono al que están unidos, forman un anillo heterocíclico de 5 a 7 miembros opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente de alquilo, ciano, halógeno, haloalquilo, alcoxi, heteroarilo y alquilheteroarilo; cada R⁹ se selecciona independientemente de alcoxi, halógeno, dialquilaminocarbonilo, alquilo, alcoxialcoxi, alcoxiheterocicloalquilalquilo, alcoxiheterocicloalquilcarbonilo, haloalquilo, haloalcoxi, heterocicloalquilalcoxi, heterocicloalquilo, heterocicloalquiloxi, hidroxi, alquilheterocicloalquilo, alquilheterocicloalquilalquilo, heterocicloalquilalquilo, alquilsulfonilo, (alquil)heterocicloalquilo, alquilheterocicloalquiloxi, heterocicloalquilheterocicloalquilo, (heterocicloalquil)heterocicloalquilo, CH₃-O-(CH₂-CH₂-O)₇-, alquilaminocarbonilo y ciano; o una sal farmacéuticamente aceptable de este. Reivindicación 13: Un proceso para la preparación de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 12, que comprende una de las siguientes etapas: (a) la reacción de un compuesto de fórmula (B1) o (B2) con una amina, en presencia de un catalizador de paladio y una base; (b) la reacción de un compuesto de fórmula (C1), con un compuesto de fórmula (C2) en presencia de una base; (c) la reacción de un compuesto de fórmula (D1) con una amina, en presencia de una base; o (d) la reacción del compuesto de fórmula (D1) con un compuesto (D2) en presencia de una base y un catalizador de paladio; en donde D2 se selecciona de (i) ácido o éster arilborónico opcionalmente sustituido y (ii) ácido o éster heteroarilborónico opcionalmente sustituido; en donde A¹, R¹, R², R³, R⁴ y R⁵ son como se definen en cualquiera de las reivindicaciones 1 a 12, Rᵃ es alquilo o cicloalquilo, Rᵇ es hidrógeno o alquilo, Rᶜ es alquilo o cicloalquilo, y X es halógeno. Reivindicación 20: Un método para el tratamiento o la profilaxis de artritis reumatoide, artritis reumatoide juvenil, esteatohepatitis no alcohólica (NASH), colangitis esclerosante primaria, vasculitis de células gigantes, enfermedades inflamatorias intestinales (IBD), ateroesclerosis, diabetes tipo 2 o glomerulonefritis, cuyo método comprende administrar una cantidad eficaz de un compuesto de fórmula (1) de acuerdo con cualquiera de las reivindicaciones 1 a 12 o una sal farmacéuticamente aceptable de este a un paciente que lo necesite.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22152241 | 2022-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128280A1 true AR128280A1 (es) | 2024-04-10 |
Family
ID=79730348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100104A AR128280A1 (es) | 2022-01-19 | 2023-01-17 | Derivados de bencimidazol piridina |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR128280A1 (es) |
| TW (1) | TW202342450A (es) |
| WO (1) | WO2023139084A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
| BR112020010364A2 (pt) * | 2017-12-02 | 2021-01-26 | Galapagos N.V. | compostos e composições farmacêuticas dos mesmos para o tratamento de doenças |
-
2023
- 2023-01-17 AR ARP230100104A patent/AR128280A1/es unknown
- 2023-01-18 WO PCT/EP2023/051053 patent/WO2023139084A1/en unknown
- 2023-01-18 TW TW112102300A patent/TW202342450A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023139084A1 (en) | 2023-07-27 |
| TW202342450A (zh) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2632940T3 (es) | Derivados de tiazol sustituidos con 2-anilin-4-arilo | |
| CA2585797C (en) | Lactam compounds and their use as pharmaceuticals | |
| AU2005316511B2 (en) | Compounds and compositions as modulators of steroidal receptors and calcium channel activities | |
| SK160598A3 (en) | Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors | |
| NZ551602A (en) | Amido compounds and their use as pharmaceuticals | |
| ES2342776T3 (es) | Moduladores benzoxazinil-amidociclopentil-heterociclicos de receptores de quimiocinas. | |
| AR089550A1 (es) | Compuestos quimicos | |
| AU2014298051A1 (en) | Novel quinazolinones as bromodomain inhibitors | |
| AR068057A1 (es) | Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. | |
| CA2989722C (en) | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy | |
| CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
| NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
| JP2012511588A5 (es) | ||
| CA2540541A1 (en) | Alkoxy substituted imidazoquinolines | |
| AR076936A1 (es) | Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1 | |
| BR112021010919A2 (pt) | Moduladores de trex1 | |
| AR088625A1 (es) | Derivados de aril-quinolina | |
| KR20200141026A (ko) | 비-융합된 티오펜 유도체 및 이의 용도 | |
| JP5208111B2 (ja) | Ｐ３８ｍａｐキナーゼ阻害剤としての１，７−ナフチリジン誘導体 | |
| US10160732B2 (en) | MIF inhibitors | |
| AR096152A1 (es) | Derivados de purina | |
| AR044906A1 (es) | Derivados de difenilpiridina, su preparacion y su aplicacion en terapeutica | |
| JP6585718B2 (ja) | 抗ヒスタミン剤としての新規ベンゾイミダゾール誘導体 | |
| AR128280A1 (es) | Derivados de bencimidazol piridina | |
| KR102092207B1 (ko) | 항바이러스 활성을 가진 메탄티온 화합물 |